New Sponge-on-a-String Test Could Help Detect Oesophageal Cancer Earlier
News Date: November 16, 2026
A new medical development in the United Kingdom could help thousands of people at increased risk of oesophageal cancer receive earlier testing through an innovative procedure known as the "sponge on a string" test.
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending two capsule sponge technologies, Cytosponge and EndoSign, for use within the NHS in England.
The development could make it easier to identify Barrett's oesophagus, a condition linked to an increased risk of developing oesophageal cancer.
The test is particularly relevant for people experiencing persistent acid reflux and heartburn alongside additional risk factors.
What Is the Sponge-on-a-String Cancer Test?
The sponge-on-a-string test is a relatively simple medical procedure designed to collect cells from the lining of the oesophagus, commonly known as the food pipe.
Unlike a traditional endoscopy, which uses a thin camera passed through the throat, this technique involves swallowing a small capsule attached to a fine thread.
Once the capsule reaches the stomach, it dissolves and releases a tiny sponge.
A trained healthcare professional then gently pulls the thread to retrieve the sponge. As it travels back through the oesophagus, it collects cells from the lining.
The collected sample is sent to a laboratory where specialists examine it for abnormalities associated with Barrett's oesophagus.
The procedure takes approximately seven minutes and does not normally require sedation.
Why Are Health Experts Recommending the Test?
Oesophageal cancer can be difficult to identify during its early stages because some symptoms resemble common digestive problems.
Persistent heartburn, acid reflux and difficulty swallowing may require medical attention, particularly when symptoms continue or become worse.
Barrett's oesophagus develops when repeated exposure to stomach acid causes changes in the cells lining the food pipe.
Although most people with Barrett's oesophagus do not develop cancer, some cases can involve further abnormal cell changes.
Identifying these changes earlier can help doctors decide whether additional investigations or treatment are necessary.
Two Innovative Tests Receive NICE Draft Recommendation
The latest NICE draft guidance supports two capsule sponge technologies:
1. Cytosponge
Cytosponge is a capsule-based test that releases a small sponge after dissolving in the stomach. It collects cells from the oesophageal lining for laboratory analysis.
2. EndoSign
EndoSign is another capsule sponge technology designed to collect oesophageal cells and help identify people who may need further investigation.
Both technologies aim to provide a less invasive initial testing option for appropriately selected patients.
The recommendation is intended for people with persistent gastro-oesophageal reflux disease and additional risk factors who do not require an urgent suspected cancer referral.
How Does the Seven-Minute Procedure Work?
The test generally follows four stages:
A patient swallows a small capsule attached to a fine thread with water.
The capsule dissolves in the stomach and releases a compressed sponge.
A healthcare professional gently retrieves the sponge using the thread.
The collected cells are sent to a laboratory for examination.
If the laboratory identifies concerning changes, the patient may be referred for an endoscopy or other appropriate investigations.
The test can help reduce the need for an initial invasive procedure in some patients.
Symptoms That Should Not Be Ignored
Health experts advise people to seek medical attention when digestive symptoms persist or become concerning.
Possible symptoms of oesophageal cancer include:
Persistent heartburn or acid reflux
Difficulty swallowing food or liquids
Pain when swallowing
Frequent indigestion or burping
Unexplained weight loss
Persistent vomiting
Pain in the throat or middle of the chest
These symptoms do not automatically mean someone has cancer. Many can be caused by other medical conditions.
However, difficulty swallowing, unexplained weight loss or worsening symptoms should be assessed by a healthcare professional.
Is the Sponge Test Available to Everyone?
No. The test is not intended as a general cancer screening procedure for everyone experiencing occasional heartburn.
NICE's draft recommendation focuses on people with persistent reflux symptoms and additional risk factors.
The test also has limitations. It cannot detect every abnormality, and some patients may still need an endoscopy.
A negative result should not be used as a reason to ignore continuing or worsening symptoms.
The recommendation concerns NHS services in England, so availability and eligibility may vary depending on local implementation.
Could This Technology Change Early Cancer Detection?
The new recommendation represents an important development in efforts to improve early detection of oesophageal cancer.
Making testing simpler and more accessible could help identify people with Barrett's oesophagus before more serious changes develop.
It could also help the NHS use specialist endoscopy services more efficiently by identifying patients who need further investigation.
However, longer-term research is still needed to establish the full impact of capsule sponge testing on cancer outcomes.
Conclusion
The sponge-on-a-string test could become an important tool in the early identification of conditions linked to oesophageal cancer.
NICE's draft recommendation for Cytosponge and EndoSign offers a promising development for eligible patients in England.
Although the procedure is not a replacement for every endoscopy or a guarantee against cancer, it could help doctors identify concerning changes earlier and guide patients towards appropriate care.
Sources: NICE, The Independent, Cancer Research UK and NHS England.
Disclaimer: This article is for general information and educational purposes only. It does not replace professional medical advice or diagnosis. NICE's November 16, 2026 recommendation is draft guidance.
